I-06 Sergei Leonov Optimal design of population pharmacokinetic/pharmacodynamic studies Wednesday 10:15-11:45 |
I-08 Earvin Liang Clinical Trial Design Optimization: A Pharmacokinetic Sampling Plan for a Phase 3 Clinical Trial in Mild Alzheimer Disease Patients Wednesday 10:15-11:45 |
I-18 Mathilde Marchand How to support a definitive bioequivalence study design using modeling and simulation Wednesday 10:15-11:45 |
I-19 John Maringwa Model-based meta-analysis of summary clinical outcome data in idiopathic pulmonary fibrosis (IPF) Wednesday 10:15-11:45 |
I-24 Veronese Mattia Optimal Experimental Design for receptor drug development with PET studies Wednesday 10:15-11:45 |
I-31 Ricardo Nalda-Molina Stochastic Simulations Assist to Improve a Poorly Designed Clinical Study for the CSF Pharmacokinetics of Doripenem Wednesday 10:15-11:45 |
I-40 Joakim Nyberg The robustness of global optimal designs Wednesday 10:15-11:45 |
II-21 Alexandre Sostelly Dose and dose schedule optimization of anticancer drugs Wednesday 15:10-16:40 |
II-32 Daniel Tatosian Strategic comparator modeling and simulation to optimize dose selection for a dose-range finding study Wednesday 15:10-16:40 |
II-39 Wanchana Ungphakorn Development of Sparse Sampling Study of Oral Ciprofloxacin for Severely Malnourished Children Wednesday 15:10-16:40 |
II-40 Pyry Välitalo Optimal design for a population pharmacokinetic study of oxycodone in preterm neonates, neonates and infants Wednesday 15:10-16:40 |
II-47 Anders Viberg Using modeling and simulation to evaluate placebo run-in for pain studies Wednesday 15:10-16:40 |
III-25 Emma Bostrom Modeling and Simulation of Pharmacokinetics and H3 Receptor Occupancy for Dose Setting in a Phase IIa Study Thursday 10:05-11:35 |
III-61 Cyrielle Dumont Optimal two-stage design for a population pharmacokinetic study in children Thursday 10:05-11:35 |
III-62 Jeroen Elassaiss-Schaap Pharmacokinetic-Pharmacodynamic Modelling & Simulation of Org 52186, a V3 antagonist, in Support of a Challenge Agent Trial Design with dDAVP Thursday 10:05-11:35 |
III-66 Mathieu Felices Dose Regimen Assessement For Oral Fexinidazole Thursday 10:05-11:35 |
IV-14 Bill Gillespie From Evidence Synthesis to Trial Optimization: The adsim Package for Model-based Simulation in Alzheimer's Disease Thursday 15:00-16:30 |
IV-20 Nathalie Gosselin Simultaneous Optimization of Sampling Strategies for Parent and Metabolite Data Taking into Account a Body Weight Distribution: Applications to Paediatric Studies Thursday 15:00-16:30 |
IV-29 Eva Hanze Comparison of longitudinal data analysis to end of treatment data analysis when evaluating precision in dose-exposure-response in neuropathic pain studies. Thursday 15:00-16:30 |
IV-50 Matts Kågedal Improved dose selection for PET occupancy studies Thursday 15:00-16:30 |
IV-61 Anders Kristoffersson Robust optimal design of ciprofloxacin time-kill curve experiments with respect to autocorrelation Thursday 15:00-16:30 |